Latest Monoclonal antibodies Stories

KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma

2013-02-26 16:27:14

Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting SOUTH SAN FRANCISCO, Calif., Feb. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) presented data from its Phase 1/2 study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) at the American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Austin, Texas. The findings demonstrated preliminary...

XBiotech Expands Portfolio to Include Biosimilars

2013-02-26 16:26:12

Proprietary Manufacturing Methods Enable Significant Cost Reduction and Flexibility to Position XBiotech as the Most Competitive Provider of Generic Antibody Therapeutics AUSTIN, Texas, Feb. 26, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an...

Asthma Drug Found Effective In Treatment Of Chronic Hives, Itchiness

2013-02-25 08:57:48

Lawrence LeBlond for redOrbit.com - Your Universe Online Though not the most common occurrence, researchers do sometimes discover drugs marketed for one particular disease, disorder or illness can work well in treating a totally different condition. One recent discovery was that of a popular diabetes drug that showed promise in treating ovarian cancer. Another--not so recent--discovery was of the antidepressant drug Wellbutrin that proved to be effective in helping smokers kick the habit....

Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy

2013-02-24 12:20:31

- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU) EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ -- Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite...

Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status

2013-02-23 12:20:18

Data presented at the 2013 American Academy of Allergy, Asthma & Immunology Annual Meeting SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ -- Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma(TM) program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. In prespecified subgroups from two paired clinical trials, tiotropium delivered once daily via the Respimat® inhaler improved lung...

iBio And Caliber Biotherapeutics Establish License And Collaboration Relationship

2013-02-19 08:32:27

NEWARK, Del. and BRYAN, Texas, Feb. 19, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), and Caliber Biotherapeutics LLC (Caliber) today announced execution of a License and Collaboration Agreement for development and production of recombinant plant-based biopharmaceuticals using iBio's proprietary iBioLaunch(TM) technology and Caliber's unique and proprietary plant-based manufacturing capabilities. (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) (Logo:...

Xencor Initiates Phase 1b/2a Trial of XmAb®5871 for Autoimmune Disease

2013-02-13 08:27:48

MONROVIA, Calif., Feb. 13, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis. XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b (FcgRIIb) pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. The trial initiation triggered a milestone...

StockCall Review on Dynavax and GlaxoSmithKline: Pharma Stocks Bet on Drug Approvals

2013-02-12 08:30:28

LONDON, February 12, 2013 /PRNewswire/ -- Any drug company's stock price hinges on the performance of its drugs. One of the very first steps involved in marketing a drug is getting the approval of FDA. Dynavax Technologies Corporation (NASDAQ: DVAX) is one such company that pointed out that the point recently. The stock plummeted when its drug candidate received poor reviews. However, the same Hepatitis B drug is now waiting for the final approval and the FDA's decision will...

Amgen Outlines Long-Term Strategy

2013-02-07 08:27:17

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming the company's core strategy will continue to focus on innovation, discovery and development of breakthrough molecules to address significant unmet medical needs, and manufacturing of high-quality...

Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX40

2013-02-04 08:25:10

MUMBAI, India, February 4, 2013 /PRNewswire/ -- - GBR 830 is the first antagonistic antibody targeting OX40 and is a potential Global First-in-class molecule - OX40, also known as CD134, plays a key role in T-cell mediated autoimmune disorders. Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel...